T14 Stock Overview
Produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥2.11 |
| 52 Week High | CN¥2.66 |
| 52 Week Low | CN¥1.66 |
| Beta | 0.80 |
| 1 Month Change | -1.86% |
| 3 Month Change | -14.57% |
| 1 Year Change | 16.57% |
| 3 Year Change | 91.82% |
| 5 Year Change | 154.22% |
| Change since IPO | 373.83% |
Recent News & Updates
Recent updates
Is Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) A Risky Investment?
Nov 03
Is Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) Expensive For A Reason? A Look At Its Intrinsic Value
Aug 08Should You Be Adding Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) To Your Watchlist Today?
Jul 21We Think Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Can Manage Its Debt With Ease
Jun 20If EPS Growth Is Important To You, Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Presents An Opportunity
Apr 17Calculating The Intrinsic Value Of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)
Mar 01Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Has A Pretty Healthy Balance Sheet
Feb 03Shareholder Returns
| T14 | SG Pharmaceuticals | SG Market | |
|---|---|---|---|
| 7D | 0.5% | 0.1% | 0.08% |
| 1Y | 16.6% | 5.7% | 14.5% |
Return vs Industry: T14 exceeded the SG Pharmaceuticals industry which returned 5.7% over the past year.
Return vs Market: T14 exceeded the SG Market which returned 14.5% over the past year.
Price Volatility
| T14 volatility | |
|---|---|
| T14 Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in SG Market | 12.4% |
| 10% least volatile stocks in SG Market | 1.9% |
Stable Share Price: T14 has not had significant price volatility in the past 3 months compared to the SG market.
Volatility Over Time: T14's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 4,619 | n/a | www.jydrt.com.cn |
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements.
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Fundamentals Summary
| T14 fundamental statistics | |
|---|---|
| Market cap | US$2.78b |
| Earnings (TTM) | US$128.68m |
| Revenue (TTM) | US$1.11b |
24.8x
P/E Ratio2.9x
P/S RatioIs T14 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| T14 income statement (TTM) | |
|---|---|
| Revenue | CN¥8.04b |
| Cost of Revenue | CN¥4.30b |
| Gross Profit | CN¥3.74b |
| Other Expenses | CN¥2.81b |
| Earnings | CN¥932.37m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 31, 2025
| Earnings per share (EPS) | 1.21 |
| Gross Margin | 46.50% |
| Net Profit Margin | 11.60% |
| Debt/Equity Ratio | 19.8% |
How did T14 perform over the long term?
See historical performance and comparisonDividends
4.3%
Current Dividend Yield106%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/25 21:03 |
| End of Day Share Price | 2025/01/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yalei Yan | Bohai Securities Co., Ltd. |
| Chengzhi Chen | CGS International |
| Shanshan Li | China Merchants Securities Co. Ltd. |